Market Intelligence for Chromatin Remodeling Targets: Comprehensive reagent solutions for SWI/SNF complex research, synthetic lethality screening, intracellular oncology target validation, and targeted protein degradation (PROTAC) development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ARID1B drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ARID1B Recombinant Protein (Full Length) HEK293 Expressed, High Purity (>95%), Sequence Verified, Theoretical MW ~225 kDa, covers ARID domain (Q8NFD5). Includes clinically reported truncation mutations (e.g., rs1251241593, rs375160616) for variant panels. |
View ARID1B Products |
| Mutant Panel | ARID1B Cancer Mutant Proteins (Truncation/LOF variants) Endotoxin <1EU/µg, Suitable for synthetic lethality binding studies and variant selectivity assays. |
View ARID1B Products |
| Gene Delivery | ARID1B Lentivirus Particles (ORF/shRNA) For stable cell line construction in synthetic lethality assays and rescue experiments. |
View ARID1B Products |
| Benchmark Ab (Detection) | Anti-ARID1B Recombinant Antibody Sequence Verified, Suitable for Western Blot, IP, ChIP, and degradation assays. |
View ARID1B Products |
| Validator | ARID1B siRNA Set (3 target-specific sequences) For knockdown verification and specificity controls. |
View ARID1B Products |
| Synthetic Lethality Partner | ARID1A Paralog subunit; Essential for ARID1B loss-of-function synthetic lethal screens and patient stratification. |
View ARID1A Products |
| Epigenetic Regulator | EZH2 PRC2 methyltransferase; Synthetic lethal target in ARID1B-mutant cancers; validated with tazemetostat. |
View EZH2 Products |
| Complex Member | SMARCA4 (BRG1) & SMARCA2 (BRM) ATPase subunits of SWI/SNF; Protein-protein interaction studies and alternative degradation targets. |
View SMARCA4 Products |
Critical Assay Requirements for ARID1B Drug Development
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Large protein size & complex folding (225 kDa chromatin remodeler) | HEK293 Expressed Full-Length Protein with Native Post-Translational Modifications; High Purity (>95%) by SEC-HPLC; Aggregate-free formulation. |
| Synthetic Lethality Screening (WT vs Cancer Mutants) | Cancer-Specific Mutant Protein Panel (Sequence Verified truncations); Wild-type orthologs for selectivity testing; Endotoxin Controlled (<1EU/µg). |
| Ternary Complex Formation for Degraders (PROTAC) | Truncated functional domains (ARID, C-terminal) expressed at >95% purity for accurate SPR and AlphaLISA assay validation. |
| Subfamily Homology Screening (ARID1B vs ARID1A) | Homolog panel proteins (ARID1A, SMARCA2, SMARCA4) strictly verified by mass spectrometry and sequence alignment; enables counter-screening for selectivity. |
| Intracellular Target Access & Stable Expression | High-Titer Lentivirus Premade Particles for stable transduction; Suitable for Co-IP, ChIP, and complex formation assays. |
| Specificity Controls & Knockdown Validation | Target-specific siRNA Set included for knockdown verification; Eliminates off-target assay artifacts. |
Live ARID1B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for ARID1B is rapidly evolving from basic tumor suppressor biology toward precision synthetic lethality and targeted protein degradation. As a core subunit of the SWI/SNF (BAF) chromatin remodeling complex, ARID1B loss-of-function mutations drive oncogenesis in endometrial, bladder, and gastric cancers. In ARID1A-deficient tumors (e.g., ovarian clear cell carcinoma), cancer cells become reliant on ARID1B, creating a synthetic lethal vulnerability.
Current R&D focuses on exploiting this dependency through EZH2 inhibition (e.g., tazemetostat, which has demonstrated clinical activity in ARID1B-mutant populations) and emerging PROTAC degraders that target ARID1B for ubiquitination. The next wave of therapeutics includes highly selective protein-protein interaction (PPI) disruptors and molecular glues that spare wild-type tissues while collapsing the BAF complex in ARID1A-mutant tumors.
Major players such as Ipsen (Epizyme), Prelude Therapeutics, Foghorn Therapeutics, and Kymera are leading the charge, with preclinical biotechs exploring additional synthetic lethal combinations (e.g., PARP inhibitors, PI3K/mTOR pathway) and CRISPR-based approaches. The field is moving from broad epigenetic inhibitors to modality-specific solutions that demand high-quality reagents for target engagement, selectivity, and cellular validation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| EZH2 Inhibitor (Synthetic Lethality) | Ipsen (Epizyme), Pfizer | ARID1B-mutant Endometrial Cancer, Solid Tumors | ARID1B Mutant vs WT Protein Panel for patient stratification assays |
| Targeted Protein Degraders (PROTAC/Molecular Glue) | Prelude Therapeutics, Foghorn Therapeutics, Kymera | ARID1A-Mutant Solid Tumors (Ovarian, Gastric) | Ternary complex validation using high-purity domain proteins and lentivirus-based cell models |
| Small Molecule PPI Inhibitors | Emerging Biotech | Ovarian & Endometrial Cancer | Selectivity assay (ARID1B vs ARID1A homolog proteins) for binding specificity |
| Gene Therapy (Coffin-Siris Syndrome) | Rare Disease Consortiums | Coffin-Siris Syndrome (Developmental disorder) | Functional Full-length Protein for rescue assay validation |
| RNA-Based Therapeutics (siRNA/CRISPR) | Academic & Preclinical Biotech | Gastric & Bladder Cancers | In vitro phenotype testing using reliable lentivirus and siRNA reagents |